PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+1.98%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.46%
AUM
$7.69B
AUM Growth
+$7.69B
(+2.2%)
Cap. Flow
+$360M
Cap. Flow
% of AUM
4.68%
Top 10 Holdings %
Top 10 Hldgs %
39.16%
Holding
167
New
26
Increased
15
Reduced
34
Closed
16
Top Buys
| 1 |
Nautilus Biotechnolgy
NAUT
|
$90M |
| 2 |
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
|
$84.7M |
| 3 |
United Therapeutics
UTHR
|
$79.3M |
| 4 |
ZY
Zymergen Inc. Common Stock
ZY
|
$65.3M |
| 5 |
Iovance Biotherapeutics
IOVA
|
$60.1M |
Top Sells
Sector Composition
| 1 | Healthcare | 85.23% |
| 2 | Financials | 0.27% |
| 3 | Industrials | 0.17% |
| 4 | Consumer Discretionary | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Health Catalyst
HCAT
$227M
| $31.4M | 0.41% |
566,084
+60,000
| +12% | +$3.33M |
|
52
Xenon Pharmaceuticals
XENE
$3.01B
| $31.3M | 0.41% |
1,678,973
+1,163,931
| +226% | +$21.7M |
|
|
DRNA
53
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $29.9M | 0.39% |
800,000
| – | – |
|
54
BioAtla
BCAB
$28.2M
| $29.1M | 0.38% |
+685,519
| New | +$29.1M |
|
55
Exact Sciences
EXAS
$9.11B
| $29M | 0.38% |
233,523
-120,000
| -34% | -$14.9M |
|
56
Immatics
IMTX
$664M
| $29M | 0.38% |
2,500,000
| – | – |
|
|
NARI
57
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $29M | 0.38% |
310,437
-254,676
| -45% | -$23.8M |
|
|
ISEE
58
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $28.9M | 0.38% |
4,585,512
| – | – |
|
|
XLRN
59
DELISTED
Acceleron Pharma Inc.
XLRN
| $28.5M | 0.37% |
+226,760
| New | +$28.5M |
|
60
Nuvation Bio
NUVB
$1.05B
| $28.3M | 0.37% |
3,041,004
| – | – |
|
61
Alphatec Holdings
ATEC
$2.31B
| $27.6M | 0.36% |
1,800,180
| – | – |
|
62
Travere Therapeutics
TVTX
$1.7B
| $26.9M | 0.35% |
1,845,555
-1,452,864
| -44% | -$21.2M |
|
|
LENZ
63
LENZ Therapeutics
LENZ
$1.11B
| $26.9M | 0.35% |
+875,093
| New | +$26.9M |
|
64
Avidity Biosciences
RNA
$6.04B
| $26.7M | 0.35% |
1,079,028
-20,000
| -2% | -$494K |
|
65
Kodiak Sciences
KOD
$444M
| $26.6M | 0.35% |
286,041
-102,967
| -26% | -$9.58M |
|
66
ADMA Biologics
ADMA
$4.06B
| $26.5M | 0.34% |
16,584,802
| – | – |
|
67
Repligen
RGEN
$6.54B
| $26.5M | 0.34% |
+132,500
| New | +$26.5M |
|
68
Arrowhead Research
ARWR
$3.76B
| $26.1M | 0.34% |
315,141
-94,200
| -23% | -$7.8M |
|
69
Lyra Therapeutics
LYRA
$11.8M
| $25.9M | 0.34% |
3,222,560
| – | – |
|
70
Cogent Biosciences
COGT
$1.8B
| $25.9M | 0.34% |
3,188,750
| – | – |
|
71
PMV Pharmaceuticals
PMVP
$78.4M
| $25.5M | 0.33% |
746,557
| – | – |
|
|
INBX
72
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $25M | 0.32% |
+907,090
| New | +$25M |
|
73
Celldex Therapeutics
CLDX
$1.57B
| $24.8M | 0.32% |
+742,699
| New | +$24.8M |
|
74
Collegium Pharmaceutical
COLL
$1.23B
| $23.1M | 0.3% |
978,277
| – | – |
|
75
Forte Biosciences
FBRX
$137M
| $23M | 0.3% |
685,000
| – | – |
|